​Cance​r Biology Faculty

   
Page    of 1
  • Luis F.Z. Batista, PhD - Understanding the role of DNA damage and RNA degradation during tissue homeostasis, regeneration, aging, and cancer
  • Carmen Bergom, MD, PhD - Identification of new targets to improve tumor radiation effectiveness and to protect normal tissues such as the heart from radiation injury
  • Kendall J. Blumer, PhD - Tumor cell biology, signal transduction, and drug development
  • Kelly L. Bolton, MD, PhD - The interplay between inherited genetic variation, environmental factors, and acquired mutations in shaping the earliest stages of carcinogenesis
  • Ron Bose, MD, PhD - Genomics and Cell Signaling in Breast Cancer
  • Yin Cao, ScD, MPH - Novel genetic, microbial, and lifestyle risk factors for lung and gastrointestinal cancers leveraging large-scale clinical and population-based cohorts with deep genomic and phenotypic data
  • Grant Challen, PhD - Understanding the genetic and epigenetic mechanisms that regulate normal and leukemic stem cells
  • Aadel A. Chaudhuri, MD, PhD - Liquid biopsy cancer detection
  • David Y. Chen, MD,PhD - Defining drivers of premalignant states in skin
  • Hong Chen, PhD - Combines biology, engineering, and medicine to develop ultrasound techniques for noninvasive, targeted, and personalized brain cancer treatment
  • Milan G. Chheda, MD - Cancer stem cells, oncolytic viruses, and functional genomics of brain tumors
  • Jaebok Choi, PhD - Understanding T cells and immunoregulatory networks in GvHD and GvL for the treatment of hematopoietic malignancies.
  • Kyunghee Choi, PhD - Angioimmune interface in development, tissue regeneration, and cancer
  • Matt Christopher, MD, PhD - Improve outcomes for patients with acute myeloid leukemia (AML) and other hematopoietic malignancies utilizing genomic and molecular biology techniques
  • Matthew A. Ciorba, MD - Tryptophan metabolism and probiotic bacteria as modifiers of intestinal cancer and inflammation
  • Roberto Civitelli, MD - Connexins, cadherins in bone cell interactions with cancer and energy metabolism
  • Graham A. Colditz, MD, DrPH - Causes and prevention of breast cancer, premalignant lesions, risk stratification
  • Richard J. Cote, MD - Pathways of tumor progression and response to therapy, particularly in bladder and prostate cancer, cancer metastasis research through analysis of lymph node and bone marrow occult metastases
  • David G. DeNardo, PhD - Molecular Mechanisms of Immune Regulation of Tumor Progression.
  • Carl DeSelm, MD, PhD - Dr. DeSelm clinically focuses on treating lymphoma, and is actively developing novel CAR T cell approaches to treating solid tumors, including lymphoma, pancreatic cancer and glioblastoma.
  • Li Ding, PhD - Cancer Proteogenomics and Cancer Models
  • Bettina F. Drake, PhD, MPH - Identifying preventive strategies to reduce cancer disparities
  • Roberta Faccio, PhD - interactions between bone and immune cells in inflammation and cancer
  • Todd A. Fehniger, MD, PhD - My laboratory is focused on the molecular mechanisms regulating natural killer cell activation, novel methods to use NK cells as immunotherapy for cancer, and lymphoma genomics.
  • Francesca Ferraro, MD, PhD - We use both mouse models and patient samples of acute myloid leukemia to understand leukemogenesis and to identify novel therapeutic targets.
  • Aimilia Gastounioti, PhD - Translational research in the intersection of computational breast imaging, artificial intelligence, and informatics towards improving breast cancer screening
  • William E. Gillanders, MD - Development of a breast cancer vaccine
  • Matthew L. Goodwin, MD, PhD - Metabolism of cancer, targeting tumor metabolism by blocking metabolic pathways
  • Abby M. Green, MD - The etiology of mutagenesis and genome instability in pediatric cancers
  • Eric Greer, PhD - Deciphering the molecular mechanisms of epigenetics and how when this goes awry diseases arise
  • Malachi Griffith, PhD - Improving our understanding of human disease biology and the development of personalized medicine strategies using genomics and informatics technologies
  • Obi L. Griffith, PhD - Development of personalized medicine strategies for cancer using genomic technologies
  • David H. Gutmann, MD, PhD - Leveraging neurogenetic disorders to study normal brain development, cancer, and autism
  • Dennis E. Hallahan, MD - The mechanisms of cell death in normal tissues during cancer therapy
  • Jason M. Held, PhD - Redox biochemistry in cell signaling and disease, Proteomics
  • Angela Hirbe, MD, PhD - Utilization of genomic information from sarcomas to better understand the pathogenesis of these tumors and to identify biomarkers and therapeutic targets for these aggressive cancers.
  • Chyi-Song Hsieh, MD, PhD - Understanding T cell tolerance to self and non-self
  • Joseph Ippolito, MD, PhD - Precision medicine through metabolism-based imaging and therapy: from laboratory to clinical translation
  • James W. Janetka, PhD - The rational structure-based drug design and synthesis for cancer and infectious disease
  • Shu (Joy) Jiang, PhD - Development of novel statistical methods for precision medicine
  • Tanner M. Johanns, MD, PhD - Novel immunotherapeutic strategies to treat solid tumors
  • Yoon A Kang, PhD - Decoding cell fate decision mechanisms to modulate lineage output for therapeutic purpose
  • Charles Kaufman, MD, PhD - Understanding and modifying the mechanisms controlling the onset of melanoma cancer by integrating zebrafish models and human disease
  • Dineo Khabele, MD - clinical and translational research in gynecologic oncology, with a focus on ovarian cancer
  • Albert H. Kim, MD, PhD - Genetic and epigenetic changes that drive malignant behavior in brain tumors
  • Eynav Klechevsky, PhD - understand the biology of different human dendritic cells and other myeloid cells as a key for manipulating immune responses in various disease conditions
  • Timothy J. Ley, MD - Study of normal versus leukemic blood cell development and immunology
  • Fuhai Li, PhD - Integrative large-scale pharmaco genomics analysis for target, signaling network, drug and drug combination discovery. Genomics data driven tumor-stromal communication discovery and modeling.
  • Kian Lim, MD, PhD - Understanding the role of inflammation in gastrointestinal cancers
  • Daniel C. Link, MD - Regulation of normal and malignant hematopoiesis
  • Gregory D. Longmore, MD - Cell Motility and Cancer Metastasis
  • Jeffrey Magee, MD, PhD - Developmental context and genetic variation as underlying mechanisms of childhood cancer
  • Nupam P. Mahajan, PhD - How tyrosine phosphorylation regulates epigenetic processes that affect cellular homeostasis and cancer cell survival
  • Christopher Maher, PhD - Translational Cancer Genomics; Noncoding RNAs
  • Ben Major, PhD - Studying how perturbation of specific signal transduction pathways contributes to the initiation, progression and dissemination of cancer
  • Daniel Marcus, PhD
  • Stephanie Markovina, MD, PhD - Studies novel metrics to serve dual purpose as biomarkers for prognosis and response to radiation therapy, as well as therapeutic targets for human solid tumors such as cervical and anal cancers.
  • Melissa Mavers, MD,PhD - Harnessing immune cells to prevent acute graft-versus-host disease
  • Helen McNeill, PhD - Coordinating cell proliferation and cell organization in organ development
  • Michael Meers, PhD - Understanding the molecular determinants of cellular diversity
  • Shamim Mollah, PhD - Utilize AI technologies to understand cellular circuitry and gene regulatory network of cancer and other rare diseases through integration of multi-omics data, special emphasis on epigenetics and the DNA–histone protein complex
  • Nima Mosammaparast, MD, PhD - Understanding how RNA modifications influence transcription, signaling, and genomic integrity
  • Mary Mullen, MD - Targeting the DNA damage response in order to overcome chemotherapy resistance
  • Stephen Oh, MD, PhD - Mechanisms of dysregulated signaling in blood cancers
  • Hua Pan, PhD
  • Gary Patti, PhD - To understand the metabolic crosstalk between cells and tissues in disease models such as cancer by using isotopes and metabolomics
  • Jacqueline Elise Payton, MD, PhD - Epigenomic aberrations in B cell lymphomas and their impact on gene regulation
  • Sid Puram, MD, PhD - Understanding the role of tumor heterogeneity in cancer biology, including its contributions to cancer development, growth, metastasis, and treatment resistance mechanisms, in order to translate these insights into new diagnostics and novel therapeutics
  • Lee Ratner, MD, PhD - Molecular biology and pathogenesis of HIV and HTLV
  • Patricia Ribeiro Pereira, PhD - Molecular imaging tools to understand tumor biology and response to therapies
  • Joshua B. Rubin, MD, PhD - Molecular mechanisms in pediatric brain tumorigenesis
  • Robert D. Schreiber, PhD - Cytokine receptor signaling and immunological protection against tumor development
  • Julie Schwarz, MD, PhD - Studying cancer therapy resistance mechanisms in humans and preclinical models
  • Jieya Shao, PhD - Molecular mechanisms and therapeutic potential of novel cancer targets
  • Monica Shokeen, PhD - Development and evaluation of small- and macro-molecular agents for multi-modal molecular imaging of cancer and cardiovascular diseases
  • Jessica M. Silva-Fisher, PhD - Long non-coding RNAs and RNA modifications in cancer metastasis and relapse
  • Nathan Singh, MD, MS - Understanding how synthetic antigen receptors direct T cell function and dysfunction in the treatment of blood cancers
  • George P. Souroullas, PhD - Understand how epigenetic mechanisms and chromatin dynamics contribute towards the development of cancer.
  • David H. Spencer, MD, PhD - My research program studies epigenetic gene regulation in cancer, with a specific emphasis on understanding how mutations in acute myeloid leukemia (AML) perturb the epigenome to alter gene expression and cause leukemia.
  • Alexander Stegh, PhD - Glioblastoma metabolism, mechanisms of immunosupression, and the development of novel gene-regulatory and immunostimulatory nanotechnologies
  • Sheila A. Stewart, PhD - Examining the role the tumor microenvironment plays in immune modulation, tumor development, metastasis and dormancy
  • Stephen M. Sykes, PhD - Identify and define those molecular features that drive leukemogenesis and then use that information to develop rational therapeutic strategies for improving outcomes in acute leukemia
  • Adetunji T. Toriola, MD, PhD - Associations of metabolic imbalance, inflamation with cancer etiology and survival
  • Brian Van Tine, MD, PhD - Understanding the metabolism of sarcomas for therapeutic development
  • Deborah J. Veis (Novack), MD, PhD - The bone microenvironment for cancer and infection
  • Priyanka Verma, PhD - Understanding DNA repair mechanisms that impact cancer etiology and responses to chemotherapies
  • Alessandro Vindigni, PhD - DNA replication and repair, and the roles of these pathways on cancer initiation, progression and response to chemotherapy and immunotherapy
  • Matthew J. Walter, MD - Genetics and genomics of blood cancer: mutation discovery and mouse models
  • Jennifer Wang, PhD - We study how subcellular compartments are organized to create functional molecular machines
  • Jeffrey P. Ward, MD, PhD - Identification of tumor specific mutant antigens recognized by the immune system as foreign that serve as the target of a T-cell response against tumors
  • Mark A. Watson, MD, PhD - Detection and molecular classification of rare tumor cells to predict and mitigate cancer metastases
  • Jason D. Weber, PhD - Tumor suppressor and oncogene networks in cancer biology
  • Katherine N. Weilbaecher, MD - Molecular mechanisms through which tumor cells metastasize to bone
  • Zhongsheng You, PhD - DNA and RNA surveillance mechanisms and their relation to cancer formation and treatment
  • Mohamed A. Zayed, MD,PhD - The mechanisms that influence arterial collateral formation and peripheral arterial atheroprogression in the setting of diabetes
  • Jin Zhang, PhD, MPHS - Deep learning; Multi-omics; Translational cancer research
  • Chao Zhou, PhD - Developing novel optical imaging technologies for biomedical applications including cancer research and tissue engineering
   
Page    of 1

Follow us: